single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

Personalized repetitive transcranial magnetic stimulation slowed cognitive and functional impairment in a phase 2 study of ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in ...

With our clinical program gaining momentum and sabirnetug’s unique selectivity for toxic amyloid beta oligomers, we are excited about the potential to offer a next-generation treatment for early ...